Clinical Features, Phenotypic Markers and Outcomes of Diffuse Large B-Cell Lymphoma between HIV-Infected and HIV-Uninfected Chinese Patients

Zhou, Ming; Cheng, Jason Chia‐Hsien; Zhao, Handan; Yang, Min; Yu, Wenjuan; Qin, Jiaying; Lang, Guanjing; Tao, Ran; Cao, Qing; Huang, Ying; Bao-cheng, Zhu; Xu, Lijun

doi:10.3390/cancers14215380

Cited by 3 publications

(2 citation statements)

References 43 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that persistent in ammation and malnutrition are both associated with unfavorable outcomes in patients with HIV-related DLBCL [13][14][15] . Given that CHE is an important indicator of chronic in ammation and malnutrition, we hypothesize that serum CHE levels may be associated with the progression and prognosis of HIV-related DLBCL.…”

Section: Introductionmentioning

confidence: 97%

Baseline Serum Cholinesterase Levels Predict the Outcome of HIV-Related Diffuse Large B-Cell Lymphoma

Zhou,

Qin,

Tong

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

Background Serum cholinesterase (CHE) has been utilized as a surrogate marker in the context of solid cancers. Nevertheless, its potential association with the prognosis of hematologic malignancies remains unclear. Methods Sixty-five patients with new-onset HIV-related diffuse large B-cell lymphoma (DLBCL) were enrolled in this retrospective study. The patients were categorized into a high CHE group (> 5500 U/L) and a low CHE group (≤ 5500 U/L). The demographic details, laboratory test results and clinical outcomes were compared between the high CHE group and the low CHE group. The overall response rate (ORR) at the end of chemotherapy was assessed by logistic regression analysis, and the 1-year overall survival rate (OS) was assessed by a multivariate Cox proportional hazards model. Results Compared with patients with high CHE, HIV-related DLBCL patients with low CHE exhibited lower levels of hemoglobin [g/L; 101.0 (81.0-115.0) vs. 123.5 (108.2–141.0), P < 0.001] and serum albumin [g/L; 31.2 ± 5.6 vs. 40.4 ± 4.5, P < 0.001] but higher levels of lactate dehydrogenase (LDH) [U/L; 404.0 (253.0-849.0) vs. 248.0 (178.3–372.0), P = 0.014] and C-reactive protein (CRP) [mg/L; 36.1 (5.8–66.6) vs. 5.1 (0.8–5.1), P < 0.001]. Moreover, HIV-related DLBCL patients with low CHE demonstrated a higher prevalence of Ann Arbor stage III/IV (92.6% vs. 56.8%, P < 0.001) and International Prognostic Index (IPI) ≥ 3 (85.2% vs. 35.1%, P = 0.002) at the time of diagnosis of DLBCL. The 1-year OS of patients was 84.2% in the high CHE group and 40.7% in the low CHE group (log-rank P < 0.001). At the end of chemotherapy, the ORR was 80.0% in the high CHE group and 31.8% in the low CHE group (P < 0.001). In multivariate analysis, CHE > 5500 U/L was independently associated with a higher ORR [adjusted odds ratio (AOR): 4.74 (1.02–22.06), P = 0.047] and lower 1-year mortality [hazard ratio (HR): 0.11 (0.03–0.52), P = 0.005]. Conclusion Based on our robust data, baseline serum CHE levels show great potential as a surrogate marker for risk stratification and for guiding treatment decisions in HIV-related DLBCL patients.

show abstract

Section: Introductionmentioning

confidence: 97%

Baseline Serum Cholinesterase Levels Predict the Outcome of HIV-Related Diffuse Large B-Cell Lymphoma

Zhou,

Qin,

Tong

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Zhou et al explore the clinical features, phenotypic markers, and outcomes of diffuse large B-cell lymphoma (DLBCL) in HIV-infected and HIV-uninfected Chinese patients. The results indicate that HIV-infected DLBCL patients exhibit distinct blood and phenotypic markers, with lower response rates and one-year survival rates, likely due to increased hematological complications and widespread organ involvement [6]. Also, another study in this Special Issue suggests that TFF1 and TFF2 may function as potential tumor suppressors in Gastric cancer (GC), offering valuable insights for predicting overall survival (OS) in GC patients.…”

mentioning

confidence: 98%

Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

Cheng,

2023

Cancers

View full text Add to dashboard Cite

show abstract

The Impact of HIV Status on Clinical Profile and Survival Among Patients With Diffuse Large B Cell Lymphoma in a Resource- Constrained Setting in the Haart Era

Mabruk,

Nyagabona,

Dharsee

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease encompassing a wide range of lymphomas, making diagnosis and treatment difficult. DLBCL accounts for half of non-Hodgkin lymphoma cases in people living with HIV/AIDS (PLWHA) and is the most common form of lymphoma in PLWHA. Even with the rollout of highly active antiretroviral therapy (HAART) and the availability of Rituximab, the treatment of DLBCL remains subpar in resource-constrained settings like Tanzania. This study aimed to identify differences in clinical profile and treatment outcomes between HIV-positive and HIV-negative DLBCL cases during the HAART era. Methods: A retrospective review of medical charts of adults with a confirmed HIV infection status treated for DLBCL with chemotherapy +/- Rituximab and consolidation radiotherapy between January 2018 and December 2019 at Ocean Road Cancer Institute (ORCI) in Dar es salaam, Tanzania, was conducted. The clinical profile and overall survival for HIV-positive DLBCL were compared to that of HIV-negative DLBCL. Vital status at three years were determined. Survival functions were estimated using the Kaplan-Meier methodology. The equality of survival functions were assessed using Log-rank tests and Cox regression analysis to identify risk factors for mortality. Results: One hundred and eleven eligible medical charts were identified. This was a cohort of black Africans with a median age of 46 (IQR: 18–81) with a 57.3% male gender distribution and 44% HIV prevalence. Overall survival (OS) at 12, 24, and 36 months for the population was 58%, 50%, and 38%, respectively, for the entire cohort. The clinical features for HIV-negative and HIV-positive DLBCL cases were similar except for the age at diagnosis, health insurance status, initial hemoglobin, functional status, and the use of salvage chemotherapy, whereby patients with HIV-positive DLBCL were more likely to be young, not have health insurance, have a low Karnofsky Performance score, have a low hemoglobin level, and be given salvage chemotherapy compared to HIV-negative DLBCL. HIV status was not associated with a reduction in 3 years overall OS [adjusted hazard ratio (aHR)1.2, (95% CI 0.7–2.1)]. Consolidation radiotherapy use was not associated with a reduction in 3 years overall OS [adjusted hazard ratio (aHR)0.2, (95% CI 0.03–1.6]. Rituximab use was associated with a marginally statistically significant increase in mortality [adjusted hazard ratio (aHR)0.53, (95% CI 0.3–1.02)]. Risk factors of three years mortality was low hemoglobin level [aHR 0.46, (95% CI 0.3–0.8)] and high IPI score [aHR 0.46, (0.2–0.8)]. Conclusion: Patients with HIV-positive DLBCL were more likely to be young, not have health insurance, have a low Karnofsky Performance score, have a low hemoglobin level, and be given salvage chemotherapy compared to HIV-negative DLBCL. HIV status and consolidation radiotherapy were not predictors of OS in the entire cohort. Rituximab use was associated with a poor 3 years OS in Tanzania patients with DLBCL especially those with HIV positive DLBCL. Low hemoglobin levels and high IPI scores were predictors of mortality.

show abstract

Clinical Features, Phenotypic Markers and Outcomes of Diffuse Large B-Cell Lymphoma between HIV-Infected and HIV-Uninfected Chinese Patients

Cited by 3 publications

References 43 publications

Baseline Serum Cholinesterase Levels Predict the Outcome of HIV-Related Diffuse Large B-Cell Lymphoma

Baseline Serum Cholinesterase Levels Predict the Outcome of HIV-Related Diffuse Large B-Cell Lymphoma

Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

The Impact of HIV Status on Clinical Profile and Survival Among Patients With Diffuse Large B Cell Lymphoma in a Resource- Constrained Setting in the Haart Era

Contact Info

Product

Resources

About